EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies

DOI: 10.1007/s11096-018-0709-6
International Journal of Clinical Pharmacy, 2018, 40, 778-782.

#	Paper	IF	Citations
7	Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	19
6	Overview of this issue: pharmacovigilance, what is new?. *International Journal of Clinical Pharmacy*, **2018**, 40, 737-739	2.3	6
5	The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy. *Biomolecules*, **2019**, 9,	5.9	25
4	Monoclonal antibody purification and its progression to commercial scale. *Biologicals*, **2020**, 63, 1-13	1.8	8
3	Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. *Therapeutic Advances in Hematology*, **2021**, 12, 2040620721989579	5.7	3
2	[Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges]. *Cadernos De Saude Publica*, **2019**, 35, e00053519	3.2	0
1	Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders. *International Immunopharmacology*, **2021**, 101, 108305	5.8	